Andrew Osbeck, PA
Medical · Wichita, KSNPI 1730199506
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.7% of the total across 466 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 33 manufacturers reported payments, led by AbbVie at 24.3% of the total. Among medical clinicians in KS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 466 payments — averaging $18.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Johnson & Johnson$2K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$580
- Lilly USA, LLC$499
- Bristol Myers Squibb$221
- plus $2K from 27 others
What the payments were for
- Food & beverage$8,56498%
- Education$2032%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 129 | $2,134 |
| Johnson & Johnson | 86 | $1,600 |
| Takeda Pharmaceuticals U.S.A., Inc. | 81 | $1,299 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 38 | $580 |
| Lilly USA, LLC | 12 | $499 |
| Bristol Myers Squibb | 13 | $221 |
| Pfizer | 16 | $214 |
| Celltrion USA Inc. | 10 | $197 |
| Janssen Scientific Affairs, LLC | 2 | $190 |
| Ipsen Biopharmaceuticals, Inc | 7 | $157 |
| QOL Medical, LLC | 6 | $143 |
| Regeneron Healthcare Solutions, Inc. | 3 | $138 |
| Ardelyx, Inc. | 7 | $138 |
| Sanofi | 6 | $137 |
| AstraZeneca | 1 | $125 |
| Gilead | 7 | $123 |
| Intercept Pharmaceuticals, Inc. | 7 | $116 |
| E.r. Squibb & Sons, L.L.C. | 1 | $102 |
| Madrigal Pharmaceuticals | 2 | $88 |
| Nestle Healthcare Nutrition Inc. | 6 | $87 |
| Aimmune Therapeutics, Inc. | 3 | $66 |
| Novo Nordisk | 2 | $56 |
| Mallinckrodt Hospital Products Inc. | 3 | $54 |
| Phathom Pharmaceuticals, Inc. | 2 | $49 |
| Fresenius Kabi USA, LLC | 2 | $48 |
| Ironwood Pharmaceuticals, Inc | 3 | $44 |
| Amgen | 2 | $35 |
| Ferring Pharmaceuticals Inc. | 2 | $32 |
| Braintree Laboratories, Inc. | 2 | $26 |
| Merck | 2 | $26 |
| Mirum Pharmaceuticals, Inc. | 1 | $17 |
| Alnylam Pharmaceuticals Inc. | 1 | $14 |
| Organon | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,767 in reported general payments places this provider in the 90th percentile of 205 medical providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 21 | $604,691 |
| CreonLipase/Protease/Amylase | 84 | $265,677 |
| ZenpepLipase/Protease/Amylase | 21 | $92,298 |
| XifaxanRifaximin | 13 | $57,510 |
| LinzessLinaclotide | 71 | $38,749 |
| TrulancePlecanatide | 31 | $17,828 |
| MotegrityPrucalopride Succinate | 16 | $8,925 |
| Dexlansoprazole DrDexlansoprazole | 36 | $5,964 |
| PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C | 22 | $3,107 |
| Budesonide DrBudesonide | 28 | $2,340 |
| ErythromycinErythromycin Base | 11 | $2,029 |
| CholestyramineCholestyramine (With Sugar) | 21 | $1,773 |
| Sucralfate | 11 | $1,704 |
| Rabeprazole Sodium | 32 | $1,469 |
| Lubiprostone | 13 | $1,292 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $1,600 | $604,69121 claims |
| AbbVieCreon, Linzess | $2,134 | $304,426155 claims |
| Aimmune Therapeutics, Inc.Zenpep | $66 | $92,29821 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance, Plenvu | $580 | $78,44566 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $1,299 | $8,92516 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 205 medical providers in Kansas.
Other medical in Wichita
- Richard AllenbachWichita$70K
- Kathryn WelchWichita$32K
- Jason MengesWichita$15K
- Trang BrownleeWichita$11K
- Susan GeorgeWichita$10K
- Lisa HarrisWichita$8K
- Christiane YourdonWichita$6K
- Kristen OchsnerWichita$5K
- Kristen WolfWichita$5K
- Christine JohnsonWichita$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.